{
    "organizations": [],
    "uuid": "419598bdda2dce6bbfbf6ba40975b7ec8b8192df",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-audentes-announces-data-from-first/brief-audentes-announces-data-from-first-dose-cohort-of-aspiro-idUSASC0A2NC",
    "ord_in_thread": 0,
    "title": "BRIEF-Audentes Announces Data From First Dose Cohort Of ASPIRO",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "May 16 (Reuters) - Audentes Therapeutics Inc:\n* AUDENTES ANNOUNCES CONTINUING POSITIVE DATA FROM FIRST DOSE COHORT OF ASPIRO, A PHASE 1/2 CLINICAL TRIAL OF AT132 IN PATIENTS WITH X-LINKED MYOTUBULAR MYOPATHY\n* PATIENT 1 HAS ACHIEVED VENTILATOR INDEPENDENCE AND ORAL FEEDING\n* SIGNIFICANT IMPROVEMENTS IN NEUROMUSCULAR AND RESPIRATORY FUNCTION AT 24-WEEK TIMEPOINT\n* HAVE BEEN TOTAL OF 24 ADVERSE EVENTS REPORTED IN ASPIRO, SIX OF WHICH WERE DETERMINED TO BE SERIOUS ADVERSE EVENTS\n* THERE HAVE BEEN AN ADDITIONAL 11 NON-SERIOUS AES IN ASPIRO, ALL DETERMINED TO BE NOT TREATMENT-RELATED Source text for Eikon: Further company coverage:\n ",
    "published": "2018-05-16T23:56:00.000+03:00",
    "crawled": "2018-05-17T14:38:44.068+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "may",
        "reuters",
        "audentes",
        "therapeutic",
        "inc",
        "audentes",
        "announces",
        "continuing",
        "positive",
        "data",
        "first",
        "dose",
        "cohort",
        "aspiro",
        "phase",
        "clinical",
        "trial",
        "at132",
        "patient",
        "myotubular",
        "myopathy",
        "patient",
        "achieved",
        "ventilator",
        "independence",
        "oral",
        "feeding",
        "significant",
        "improvement",
        "neuromuscular",
        "respiratory",
        "function",
        "timepoint",
        "total",
        "adverse",
        "event",
        "reported",
        "aspiro",
        "six",
        "determined",
        "serious",
        "adverse",
        "event",
        "additional",
        "aes",
        "aspiro",
        "determined",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}